Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix

被引:164
作者
Ohlsson, LB [1 ]
Varas, L [1 ]
Kjellman, C [1 ]
Edvardsen, K [1 ]
Lindvall, M [1 ]
机构
[1] Univ Lund, Dept Cell & Mol Biol, Sect Tumor Immunol, Lund, Sweden
关键词
gelatin matrix; colon carcinoma; rat; mesenchymal progenitor cell; in vivo; irnmunohistochemistry;
D O I
10.1016/j.yexmp.2003.06.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
A preformed gelatin matrix containing adherent rat colon carcinoma cells was transplanted subcutaneously into rats to analyze the outgrowth of the tumor and the inflammatory response. The gelatin matrix simplifies the precise localization of the tumor cells early after implantation and allows the gelatin piece with a growing tumor to be dissected for analysis in vitro, after various times in vivo. The immortalized mesenchymal progenitor cell line MPC1cE was cocultured with rat colon carcinoma cells in vivo in gelatin matrix. The mesenchymal progenitor cells inhibited the outgrowth of the rat colon carcinoma and a complete inhibition was seen if the number of mesenchymal progenitor cells were at least equal to the number of tumor cells. The mixture of tumor cells and mesenchymal progenitor cells induced more infiltration of monocytes and granulocytes than tumor cells or mesenchymal progenitor cells alone. Infiltration of T cells and CD31(+) endothelial cells correlated to the presence of tumor cells and not to mesenchymal progenitor cells. These findings suggest that tumor cell culture in vivo in a gelatin matrix is effective for early localization of tumor cells in vivo and that mesenchymal progenitor cells effectively inhibit the growth of the tumor cells in vivo. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 16 条
  • [1] Bone marrow stromal stem cells: Nature, biology, and potential applications
    Bianco, P
    Riminucci, M
    Gronthos, S
    Robey, PG
    [J]. STEM CELLS, 2001, 19 (03) : 180 - 192
  • [2] Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system
    Bonnotte, B
    Larmonier, N
    Favre, N
    Fromentin, A
    Moutet, M
    Martin, M
    Gurbuxani, S
    Solary, E
    Chauffert, B
    Martin, F
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (09) : 5077 - 5083
  • [3] USE OF A MONOCLONAL RAT ANTI-MOUSE IG LIGHT CHAIN (RAMOL-1) ANTIBODY REDUCES BACKGROUND BINDING IN IMMUNOHISTOCHEMICAL AND FLUORESCENT-ANTIBODY ANALYSIS
    BRODIN, NT
    JANSSON, B
    HEDLUND, G
    SJOGREN, HO
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1989, 37 (07) : 1013 - 1024
  • [4] SITE-DIRECTED MUTAGENESIS OF GLYCOSYLATION SITES IN THE TRANSFORMING GROWTH FACTOR-BETA-1 (TGF-BETA-1) AND TGF-BETA-2 (414) PRECURSORS AND OF CYSTEINE RESIDUES WITHIN MATURE TGF-BETA-1 - EFFECTS ON SECRETION AND BIOACTIVITY
    BRUNNER, AM
    LIOUBIN, MN
    MARQUARDT, H
    MALACKO, AR
    WANG, WC
    SHAPIRO, RA
    NEUBAUER, M
    COOK, J
    MADISEN, L
    PURCHIO, AF
    [J]. MOLECULAR ENDOCRINOLOGY, 1992, 6 (10) : 1691 - 1700
  • [5] 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
    Cannons, JL
    Lau, P
    Ghumman, B
    DeBenedette, MA
    Yagita, H
    Okumura, K
    Watts, TH
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (03) : 1313 - 1324
  • [6] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
    Hanahan, D
    Folkman, J
    [J]. CELL, 1996, 86 (03) : 353 - 364
  • [7] The hallmarks of cancer
    Hanahan, D
    Weinberg, RA
    [J]. CELL, 2000, 100 (01) : 57 - 70
  • [8] RE-EXAMINATION AND FURTHER DEVELOPMENT OF A PRECISE AND RAPID DYE METHOD FOR MEASURING CELL-GROWTH CELL KILL
    HANSEN, MB
    NIELSEN, SE
    BERG, K
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1989, 119 (02) : 203 - 210
  • [9] Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma
    Hegardt, P
    Widegren, B
    Li, L
    Sjögren, B
    Kjellman, C
    Sur, I
    Sjögren, HO
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (09) : 491 - 501
  • [10] HELLSTROM I, 1990, CANCER RES, V50, P2183